학술논문

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
Document Type
Article
Source
In: The Lancet Neurology. (The Lancet Neurology, July 2022, 21(7):608-619)
Subject
Language
English
ISSN
14744465
14744422